1249 related articles for article (PubMed ID: 28287848)
1. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
3. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.
Volonté A; Di Tomaso T; Spinelli M; Todaro M; Sanvito F; Albarello L; Bissolati M; Ghirardelli L; Orsenigo E; Ferrone S; Doglioni C; Stassi G; Dellabona P; Staudacher C; Parmiani G; Maccalli C
J Immunol; 2014 Jan; 192(1):523-32. PubMed ID: 24277698
[TBL] [Abstract][Full Text] [Related]
4. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
5. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
6. The role of cancer stem cells in the modulation of anti-tumor immune responses.
Maccalli C; Rasul KI; Elawad M; Ferrone S
Semin Cancer Biol; 2018 Dec; 53():189-200. PubMed ID: 30261276
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
9. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
10. The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.
Bellamkonda K; Chandrashekar NK; Osman J; Selvanesan BC; Savari S; Sjölander A
BMC Cancer; 2016 Jul; 16():425. PubMed ID: 27388564
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
12. Adding fuel to the fire: immunogenic intensification.
O'Sullivan Coyne G; Gulley JL
Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
[TBL] [Abstract][Full Text] [Related]
13. [The biological rationale for immunotherapy in cancer].
Benzaquen J; Marquette CH; Glaichenhaus N; Leroy S; Hofman P; Ilié M
Rev Mal Respir; 2018 Feb; 35(2):206-222. PubMed ID: 29428191
[TBL] [Abstract][Full Text] [Related]
14. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
15. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
16. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors.
Sabbatino F; Wang Y; Wang X; Schwab JH; Ferrone S; Ferrone CR
Semin Oncol; 2014 Oct; 41(5):685-99. PubMed ID: 25440613
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1.
Shirosaki T; Kawai N; Ebihara Y; Murai A; Kubo T; Morita R; Murata K; Kanaseki T; Tsukahara T; Shichinohe T; Hirohashi Y; Hirano S; Torigoe T
Anticancer Res; 2024 May; 44(5):1877-1883. PubMed ID: 38677758
[TBL] [Abstract][Full Text] [Related]
19. Immune evasion by cancer stem cells.
Tsuchiya H; Shiota G
Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
[TBL] [Abstract][Full Text] [Related]
20. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
